Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Rueda

Showing results (201-210 of 220) with videos related to

Pageof 22
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|November 10, 2011
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistanceJean-Pierre Gillet, Anna Maria Calcagno, Sudhir Varma, et al.
Plos One|December 6, 2011
Inhibition of Hedgehog signaling antagonizes serous ovarian cancer growth in a primary xenograft modelChristopher K McCann, Whitfield B Growdon, Kashmira Kulkarni-Datar, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|July 24, 2023
Inaugurating High-Throughput Profiling of Extracellular Vesicles for Earlier Ovarian Cancer DetectionAla Jo, Allen Green, Jamie E Medina, et al.
Cancer Research|May 2, 2024
Correction: Antibody-Peptide Epitope Conjugates for Personalized Cancer TherapySongfa Zhang, Chuan Yan, David G Millar, et al.
Plos One|February 23, 2012
Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcomeDavid A Engler, Sumeet Gupta, Whitfield B Growdon, et al.
Cancer Research|December 30, 2021
Antibody-Peptide Epitope Conjugates for Personalized Cancer TherapySongfa Zhang, Chuan Yan, David G Millar, et al.
Cancers|June 2, 2021
Enhanced Efficacy of Aurora Kinase Inhibitors in G2/M Checkpoint Deficient <i>TP53</i> Mutant Uterine Carcinomas Is Linked to the Summation of LKB1-AKT-p53 InteractionsKatherine N Lynch, Joyce F Liu, Nikolas Kesten, et al.
British Journal of Cancer|March 4, 2024
Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinomaYusuke Matoba, Dominique T Zarrella, Venkatesh Pooladanda, et al.
Nature Communications|May 7, 2024
Author Correction: Meiotic protein SYCP2 confers resistance to DNA-damaging agents through R-loop-mediated DNA repairYumin Wang, Boya Gao, Luyuan Zhang, et al.
Biorxiv : the Preprint Server for Biology|July 16, 2025
Paclitaxel-induced mitotic arrest results in a convergence of apoptotic dependencies that can be safely exploited by BCL-X<sub>L</sub> degradation to overcome cancer chemoresistanceXingping Qin, Adam Presser, Lissah Johnson, et al.
Pageof 22

Showing results (201-210 of 220) with videos related to

Sort By:
Pageof 22
Proceedings of the National Academy of Sciences of the United States of America|November 10, 2011
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistanceJean-Pierre Gillet, Anna Maria Calcagno, Sudhir Varma, et al.
Plos One|December 6, 2011
Inhibition of Hedgehog signaling antagonizes serous ovarian cancer growth in a primary xenograft modelChristopher K McCann, Whitfield B Growdon, Kashmira Kulkarni-Datar, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|July 24, 2023
Inaugurating High-Throughput Profiling of Extracellular Vesicles for Earlier Ovarian Cancer DetectionAla Jo, Allen Green, Jamie E Medina, et al.
Cancer Research|May 2, 2024
Correction: Antibody-Peptide Epitope Conjugates for Personalized Cancer TherapySongfa Zhang, Chuan Yan, David G Millar, et al.
Plos One|February 23, 2012
Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcomeDavid A Engler, Sumeet Gupta, Whitfield B Growdon, et al.
Cancer Research|December 30, 2021
Antibody-Peptide Epitope Conjugates for Personalized Cancer TherapySongfa Zhang, Chuan Yan, David G Millar, et al.
Cancers|June 2, 2021
Enhanced Efficacy of Aurora Kinase Inhibitors in G2/M Checkpoint Deficient <i>TP53</i> Mutant Uterine Carcinomas Is Linked to the Summation of LKB1-AKT-p53 InteractionsKatherine N Lynch, Joyce F Liu, Nikolas Kesten, et al.
British Journal of Cancer|March 4, 2024
Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinomaYusuke Matoba, Dominique T Zarrella, Venkatesh Pooladanda, et al.
Nature Communications|May 7, 2024
Author Correction: Meiotic protein SYCP2 confers resistance to DNA-damaging agents through R-loop-mediated DNA repairYumin Wang, Boya Gao, Luyuan Zhang, et al.
Biorxiv : the Preprint Server for Biology|July 16, 2025
Paclitaxel-induced mitotic arrest results in a convergence of apoptotic dependencies that can be safely exploited by BCL-X<sub>L</sub> degradation to overcome cancer chemoresistanceXingping Qin, Adam Presser, Lissah Johnson, et al.
Pageof 22